| 2026-08-26 | Press release | VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets · H1 2026 |
| 2026-08-26 | Press release | Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis Published in Critical Care Medicine |
| 2026-08-24 | 8-K | Form 8-K, Item 3.02 |
| 2026-08-13 | Press release | VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-13 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-12 | Press release | Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing |
| 2026-08-11 | Press release | VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update |
| 2026-08-07 | 8-K | Form 8-K, Item 3.02 |
| 2026-08-05 | Press release | Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology |
| 2026-07-30 | Press release | Volition Advances Nu.Q® NETs Platform Towards Commercialization |
| 2026-07-21 | 8-K | Form 8-K, Item 5.03 |
| 2026-07-07 | Press release | VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test |
| 2026-06-18 | 8-K | Form 8-K, Item 3.02 |
| 2026-06-17 | Press release | VolitionRx Announces Collaboration with Sysmex |
| 2026-06-10 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-07 | Press release | VolitionRx Announces Pricing of $4.6 Million Public Offering |
| 2026-06-03 | Press release | VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones |
| 2026-06-02 | Proxy | Definitive proxy statement |
| 2026-05-27 | Press release | VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets · Q1 2026 |
| 2026-05-22 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-15 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-14 | Press release | VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update |
| 2026-05-14 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-14 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-14 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-11 | Press release | VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update |
| 2026-04-30 | 10-K | Annual report on Form 10-K/A, FY25 |
| 2026-04-28 | 8-K | Form 8-K, Item 3.03 |
| 2026-04-23 | 8-K | Form 8-K, Item 3.01 |
| 2026-04-17 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-02 | Transcript | Q4 FY25 earnings call transcript |
| 2026-04-01 | 8-K | Form 8-K, Item 5.07 |
| 2026-03-31 | Press release | VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update |
| 2026-03-31 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-31 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-25 | Press release | VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update |
| 2026-02-20 | 8-K | Form 8-K, Item 3.02 |
| 2026-02-11 | Proxy | Definitive proxy statement |